Construction work for the greenfield production will start in the third quarter of this year. Over the next two years, Helvoet Pharma intends to spend some EUR14m. The new plant will be operational in 2012.
The new plant will be located near Pune (Maharashtra) in a newly developed industrial zone with a secure energy supply, good transport connections and access to trained personnel. If required, the new facility can be expanded modularly in the future.
With this facility, Helvoet Pharma is further strengthening its market position in India and establishing its first operational platform in Asia.
Helvoet Pharma’s decision to build its own manufacturing plant in India has been made to leverage the country’s position as the centre of excellence for generic and branded pharmaceutical products.
Reportedly, India has the highest number of FDA approved plants outside the US and is expected to become a significant healthcare consumer market.